- Home
- BME vs DRTS Comparison
BME vs DRTS Comparison
Compare BME & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BME | DRTS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.5M | 607.1M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | BME | DRTS |
|---|---|---|
| Price | $42.20 | $7.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 33.2K | ★ 313.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $2.30 |
| 52 Week High | $42.63 | $8.60 |
Technical Indicators
Market Signals| Indicator | BME | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 60.08 |
| Support Level | $41.21 | $6.57 |
| Resistance Level | $42.46 | N/A |
| Average True Range (ATR) | 0.45 | 0.51 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 57.84 | 68.66 |
Price Performance
Historical ComparisonAbout BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.